#USA #Chicago #Seegene #CURECA #STAgora

Seegene's Groundbreaking Technologies at ADLM 2025

August 5, 2025, marks a pivotal moment in the molecular diagnostics landscape as Seegene Inc., a prominent player in the industry, showcased two groundbreaking technologies at the ADLM 2025 conference in Chicago. These innovations, CURECA™ and STAgora™, are poised to revolutionize laboratory automation and enhance the monitoring of infectious diseases.

Introduction of CURECA™ and STAgora™

During a press conference held on July 30, Dr. Jong-Yoon Chun, the Chairman and CEO of Seegene, elaborated on the significance of these technologies. CURECA™ stands as the world’s first fully unattended PCR automation system, while STAgora™ is an advanced real-time data analytics platform designed to improve diagnostic practices.

Dr. Chun articulated the overarching vision behind these innovations: "Our goal is to enable laboratories worldwide to automate complex testing workflows and utilize diagnostic data more effectively, ultimately fostering a global environment free from diseases."

CURECA™: A New Era of Automation

CURECA™ is designed to automate every step of the PCR testing process, including the traditionally manual pre-treatment phase. Seegene emphasizes that true automation in diagnostics hinges on three essential factors: operation without highly trained personnel, continuous, round-the-clock processing, and seamless specimen input. CURECA™ is built to fulfill all these criteria.

The system features the CURECA™ Prep module, which efficiently processes various specimen types including urine, blood, sputum, and stool. This addresses a longstanding challenge in automation, enabling laboratories to streamline workflows significantly. Without requiring manual intervention, CURECA™ handles the entire PCR workflow, from sample loading and nucleic acid extraction to amplification and result analysis.

Aiming to minimize human error and enhance operational efficiency, the system is structured for nonstop operation. Furthermore, it can be configured to align with the scales and needs of different laboratories, with the potential for future applications in other testing fields such as clinical chemistry and immunodiagnostics.

STAgora™: Enhancing Data-Driven Decisions

In tandem with CURECA™, STAgora™ represents a paradigm shift in how laboratories handle and interpret PCR testing data. This platform is engineered to gather and analyze data in real-time, providing context that is crucial for informed decisions during diagnostic workflows. Equipped with over 40 analytical tools, STAgora™ offers functionalities such as monitoring infection trends, hospital-specific positivity rates, and patterns of multi-pathogen co-infections.

This integrated platform enables hospitals to construct their own statistical datasets and allows for comparisons across institutions, accelerating the detection of infection trends. Data shared via STAgora™ is anonymized and structured in accordance with each institution's requirements, facilitating secure, real-time exchanges at local, national, or even international levels.

A Vision for the Future

Dr. Chun reaffirmed Seegene's commitment to a future that is free from diseases. The introduction of CURECA™ and STAgora™ completes the company's suite of five core technological pillars, which includes proprietary PCR technology, the Seegene Digitalized Development System (SGDDS), and a global technology-sharing initiative.

This groundbreaking approach caught the attention of industry experts at ADLM 2025. For instance, Jamel Giuma, the President and CEO of Miami-based JTG Consulting Group, expressed enthusiasm for CURECA™: "I’ve seen many innovations at ADLM, and CURECA™ stands out as one of the most transformative. It has the potential to revolutionize laboratory workflows and significantly enhance operational efficiency."

Dr. Chun concluded, "Just as smartphones have transformed communication and electric vehicles have reshaped transportation, we believe CURECA™ and STAgora™ will redefine the diagnostic landscape, enabling laboratories to achieve full automation, unlock the true potential of diagnostic data, and contribute to a healthier, disease-free world."

Disclaimer: CURECA™ and STAgora™ are pre-commercial technologies currently under development and are not available for commercial diagnostic use in any jurisdiction.